104 research outputs found
Histological response of peritoneal carcinomatosis after hyperthermic intraperitoneal chemoperfusion (HIPEC) in experimental investigations
BACKGROUND: In selected patients with peritoneal carcinomatosis from colorectal cancer prognosis can be improved by hyperthermic intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery. The aim of this study was to evaluate the tumor response of peritoneal carcinomatosis in tumor-bearing rats treated with HIPEC. METHODS: CC531 colon carcinoma (2,5 × 10(6 )cells), implanted intraperitoneally in Wag/Rija rats, was treated by hyperthermic intraperitoneal chemotherapy. After 10 days of tumor growth the animals were randomized into five groups of six animals each: group I: control (n = 6), group II: sham operated animals (n = 6), group III: hyperthermic intraperitoneal perfusion (HIP) without cytostatic drugs, group IV: HIPEC with mitomycin C in a concentration of 15 mg/m(2 )(n = 6), group V: mitomycin C i.p. alone in a concentration of 10 mg/m(2 )(n = 6). After 10 days the extent of tumor spread and histological outcome were analysed by autopsy. RESULTS: All control animals developed extensive intraperitoneal tumor growth. Histological tumor load was significantly reduced in group III and group V and was lowest in group IV. In group II tumor load was significantly higher than in group I. Implanted metastases were significantly decreased in group IV compared with group I and group II. CONCLUSION: These findings indicate that HIPEC is an effective treatment for peritoneal carcinomatosis in this animal model. HIPEC reduced macroscopic and microscopic intraperitoneal tumor spread
Survival prognostic factors in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy treatment: analysis from a single oncological center
Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis
A dose-finding study was performed to evaluate the dose-limiting
toxicity (DLT), maximum-tolerated dose (MTD) and the recommended dose (RD) of
escalating the doses of capecitabine and fixed doses of irinotecan and
oxaliplatin on a biweekly schedule for metastatic colorectal cancer patients
(mCRC). A pharmacogenomic analysis was performed to investigate the association
between SNPs and treatment outcome. METHODS: Eighty-seven chemotherapy-naive mCRC
patients were recruited through a two-step study design; 27 were included in the
dose-finding study and 60 in the pharmacogenomic analysis. Oxaliplatin (85 mg
m(-2)) and CPT-11 (150 mg m(-2)), both on day 1, and capecitabine doses ranging
from 850 to 1500 mg m(-2) bid on days 1-7 were explored. Peripheral blood samples
were used to genotype 13 SNPs in 10 genes related to drug metabolism or efficacy.
Univariate and multivariate Cox analysis was performed to examine associations
between SNPs, ORR and PFS. RESULTS: The capecitabine RD was 1000 mg m(-2) bid.
Diarrhoea and neutropenia were the DLTs. After a median follow-up of 52.5 months,
the median PFS and OS were 12 (95% CI; 10.6-13.4) and 27 months (95% CI;
17.2-36.8), respectively.The GSTP1-G genotype, the Kohne low-risk category and
use of a consolidation approach strongly correlated with decreased risk of
progression. Patients with all favourable variables showed a median PFS of 42
months vs 3.4 months in the group with all adverse factors. A superior clinical
response was obtained in patients with one GSTP1-G allele as compared with
GSTP1-AA carriers (P=0.004). CONCLUSION: First-line therapy with oxaliplatin,
irinotecan and capecitabine is efficient and well-tolerated. The GSTP1
polymorphism A>G status was significantly associated with ORR and PFS in mCRC
treated with this triplet therapy
Versican and vascular endothelial growth factor expression levels in peritoneal metastases from colorectal cancer are associated with survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
Morbidity Associated with Colostomy Reversal After Cytoreductive Surgery and HIPEC
ABSTRACT Background. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has improved the survival in selected colorectal cancer patients with peritoneal metastases. In these patients, the risk of a low anastomosis is sometimes diminished through the creation of a colostomy. Currently, the morbidity and mortality associated with the reversal of the colostomy in this population is unknown. Methods. Our study involved two prospectively collected databases including all patients who underwent CRS-HI-PEC. We identified all consecutive patients who had a colostomy and requested a reversal. The associations between four clinical and ten treatment-related factors with the outcome of the reversal procedure were determined by univariate analysis. Results. 21 of 336 patients (6.3 %) with a stoma with a mean age of 50.8 (standard deviation 10.2) years underwent a reversal procedure. One patient was classified as American Society of Anesthesiologists (ASA) grade III, 6 as ASA grade II, and the remaining as ASA grade I. Median time elapsed between HIPEC and reversal was 394 days (range 133-1194 days). No life-threatening complications or mortality were observed after reversal. The reversal-related morbidity was 67 %. Infectious complications were observed in 7 patients (33 %). Infectious complications after HIPEC were negatively correlated with the ultimate restoration of bowel continuity (P = 0.05). Bowel continuity was successfully restored in 71 % of the patients. Conclusions. Although the restoration of bowel continuity after CRS-HIPEC was successful in most patients, a relatively high complication rate was observed. Patients with infectious complications after HIPEC have a diminished chance of successful restoration of bowel continuity. Colorectal carcinoma is the third most common cancer worldwide, accounting for approximately 1 million newly diagnosed patients per year and over 600,000 deaths due to this disease. 1 Approximately 10-25 % of colorectal cancer patients develop peritoneal metastases, of whom 25 % present with the peritoneum as the sole site of distant metastases. 2-4 The peritoneum is a thin membrane that covers the abdominal wall and internal organs. 5 Peritoneal metastases are believed to be the result of tumor cell shedding into the peritoneal cavity, either spontaneously or as a result of spill during surgical procedures, ultimately resulting in the development of tumor deposits on the peritoneal surface
Determinantes organizacionais e estratégicos do grau de internacionalização de empresas brasileiras
- …